Cardiorenal Syndrome: Characteristics and Prognostic Impact in Advanced Heart Failure (CARAVEL)
Advanced heart failure (AHF) represents the end stage of chronic heart failure with reduced ejection fraction and affects up to 10% of patients with heart failure. These patients have refractory disease despite optimal guideline-directed medical therapy, and their management is discussed within a multidisciplinary "Heart Team".
Renal dysfunction is highly prevalent in this population. The coexistence of cardiac and renal dysfunction has been classified under the entity of cardiorenal syndrome. Impaired renal function is an independent predictor of adverse cardiovascular and renal outcomes, including death, heart failure decompensation, worsening renal function, and the need for renal replacement therapy. However, patients with AHF remain a particularly complex population, and the lack of longitudinal biological data and limited understanding of the dynamics of cardiorenal syndrome in relation to therapeutic interventions make prognosis assessment and individualized management challenging.
In addition, little is known about renal tubular function in AHF, despite its central role in hydro-electrolytic balance regulation. Biomarkers of tubular injury such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have shown prognostic value in therapeutic studies, but their relationship with cardiac function and outcomes in advanced heart failure remains insufficiently characterized.
The primary objective of this study is to evaluate renal function parameters and their evolution over time through measurement of glomerular filtration rate (GFR) and assessment of tubular function in patients with advanced heart failure, and to investigate their association with major adverse cardiovascular events.
This is a prospective, single-center RIPH2 cohort study including 100 patients aged 18 to 75 years managed for advanced heart failure at the Louis Pradel Cardiovascular Hospital (Hospices Civils de Lyon, France). Patients will be followed according to standard care at 6, 12, 18, and 24 months. More comprehensive nephrological and cardiological evaluations will be performed at baseline, 12 months, and 24 months. Biobanking and quality-of-life questionnaires will also be conducted during these visits. Blood and urine samples will be collected at baseline and 12 months for NGAL et KIM-1 analysis. In addition, a subgroup of 50 consenting patients without contraindications will undergo multiparametric non-contrast renal MRI combined with tissue sodium quantification using 23Na MRI of the leg.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Nathan MEWTON, Pr
- Numero di telefono: +33 04 72 35 71 70
- Email: nathan.mewton@chu-lyon.fr
Luoghi di studio
-
-
Rhone
-
Bron, Rhone, Francia, 69500
- Hospices Civils de Lyon
-
Contatto:
- Nathan MEWTON, Pr
- Numero di telefono: +33 04 72 35 71 70
- Email: nathan.mewton@chu-lyon.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Written informed consent signed by the patient,
- Age ≥ 18 years and ≤ 75 years,
Patient with advanced heart failure confirmed by criteria of severe cardiac dysfunction documented in a stable condition, with at least one of the following parameters at baseline:
- LVEF ≤ 35%,
- Elevated BNP or NT-proBNP levels (>200 ng/L for BNP and >1000 ng/L for NT-proBNP),
- NYHA class ≥ 3,
- At least one hospitalization for heart failure decompensation within the past 24 months,
- Optimized medical treatment for heart failure according to French/European cardiology guidelines at the maximum tolerated dose for >30 days.
Exclusion Criteria:
- Presence of severe extracardiac disease with a life expectancy < 1 year,
- Patient with end-stage renal disease (GFR <15 mL/min/1.73 m²) or on dialysis,
- History of heart, kidney, or other solid organ transplantation,
- Patient in cardiogenic shock,
- INTERMACS profile ≤ 3,
- Pregnant, parturient, or breastfeeding women*,
- Individuals deprived of liberty by judicial or administrative decision,
- Individuals under psychiatric care,
- Individuals admitted to a health or social institution for purposes other than research,
- Adults under legal protection (guardianship or curatorship),
- Individuals not affiliated with a social security system or equivalent coverage.
- Contraindication to multiparametric renal MRI combined with tissue sodium measurement using non-contrast 23Na MRI of the leg (including inability to undergo MRI as judged by the investigator).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Patients with cardiorenal syndrome
Patients with cardiorenal syndrome will be followed for 2 years in nephrology and cardiology according to standard of care.
|
Patients with cardiorenal syndrome will be followed for 2 years in nephrology and cardiology according to standard of care.
In addition, as part of the research, they will complete quality-of-life questionnaires and provide blood, urine, and stool samples for testing and biobanking.
An MRI will also be performed for patients participating in the ancillary study.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Occurrence of major cardiovascular events during the first 24 months
Lasso di tempo: At 12 and 24 months
|
The primary endpoint of this study is the occurrence of major cardiovascular events during the first 24 months: all-cause mortality, heart transplantation, implantation of a ventricular assist device, hospitalization for heart failure, or worsening ambulatory heart failure. The association between baseline renal function parameters (GFR, NGA, and KIM-1) and the occurrence of events during the first 24 months will be evaluated, as well as the association between renal function parameters at 12 months and the occurrence of major cardiovascular events between 12 and 24 months. |
At 12 and 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Blood and urinary levels of NGAL and KIM-1
Lasso di tempo: at baseline and at 12 months
|
Blood and urinary measurement of NGAL (neutrophil gelatinase-associated lipocalin) and KIM-1 (kidney injury molecule-1),
|
at baseline and at 12 months
|
|
Occurrence of major adverse renal events
Lasso di tempo: at baseline, 12 and 24 months
|
Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes. The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months. Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes. The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months. |
at baseline, 12 and 24 months
|
|
Occurrence of heart failure decompensation events
Lasso di tempo: at baseline, 12 and 24 months
|
Occurrence of heart failure decompensation events (hospitalization, ventricular assist device implantation, or outpatient worsening) during the first 24 months.
The association between specific biomarkers of renal tubular injury (serum and urinary NGAL and KIM-1) at baseline and heart failure decompensation events during the first 24 months will be analysed, as well as the association between changes in specific biomarkers of renal tubular injury between baseline and 12 months and the occurrence of heart failure decompensation events between 12 and 24 months.
|
at baseline, 12 and 24 months
|
|
Clinical data collected over a 24-month follow-up period
Lasso di tempo: over 24 months
|
Description of the study population over 24 months of follow-up (clinical, paraclinical, therapeutic characteristics, and serious adverse events),
|
over 24 months
|
|
Score of KCCQ questionnaire
Lasso di tempo: at baseline, and at 6, 12, 18, and 24 months
|
Each item of KCCQ questionnaire is scored on a 5-point Likert scale and transformed to a 0-100 scale, with higher scores indicating better health status.
|
at baseline, and at 6, 12, 18, and 24 months
|
|
Biomarkers identification
Lasso di tempo: At baseline, 12 months and 24 months
|
IBiomarkers identification in biological samples collected in the study biocollection.
|
At baseline, 12 months and 24 months
|
|
Multiparametric renal MRI
Lasso di tempo: at baseline and at 12 months
|
Multiparametric renal MRI (BOLD, diffusion, T1 and T2 mapping) in a subgroup of 50 voluntary patients (optional examination)
|
at baseline and at 12 months
|
|
Tissue sodium measurement
Lasso di tempo: at baseline and at 12 months.
|
Tissue sodium measurement using 23Na MRI of the leg in a subgroup of 50 voluntary patients (optional examination)
|
at baseline and at 12 months.
|
|
Score of Morisky self-questionnaire MMAS-4
Lasso di tempo: at baseline, and at 6, 12, 18, and 24 months,
|
Morisky self-questionnaire MMAS-4 is a generic patient-reported questionnaire used to assess medication adherence.
The scale consists of four items, each scored as 0 for "Yes" and 1 for "No".
The item scores are summed to yield a total score ranging from 0 to 4. Higher scores indicate better medication adherence.
|
at baseline, and at 6, 12, 18, and 24 months,
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 69HCL20_0968
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .